Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
NCT07314203Phase 3Not yet recruiting
- Sponsor
- Fujian Medical University
- Start
- Dec 2026
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised trial of adebrelimab in gastric cancer (GC), sponsored by Fujian Medical University. Primary endpoint: Objective Response Rate at 1 day. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT07314203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07314203.